Welcome to: Rimonabant Information Source (rimonabant for sale)

buy Rimonabant and lose weight
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 

Effective weight loss with Rimonabant

6 kg of obese and overweight patients and 1 year after treatment, with about 50% of patients and achieve a weight loss of [greater than or equal to] 5%. A study has shown that weight loss is maintained for up to 2 years. The drug also improves glycemic lipids and cardiovascular risk factors, including high-density lipoprotein cholesterol and insulin resistance, and reduce waist circumference, thus reducing the prevalence of metabolic syndrome. Treatment of obesity and overweight diabetic patients with rimonabant decreases glycosylated hemoglobin ([HbA.sub. 1c]), including patients and previously untreated diabetes. The effect of rimonabant seems partly independent of weight loss. Rimonabant 20 mg / day is generally well tolerated, with mild to moderate transient side effects such as nausea, diarrhea, dizziness and anxiety.

Rimonabant Pricelist

Please wait while we load the price list
Acomplia Rimonabant slimming pills are manufactured by French pharmaceutical company Sanofi-Aventis. Many clinical trials of this weight loss medication have proved that it helps reduce up to ten percent of body weight. Ingredients of Acomplia The main ingredient in Acomplia is Rimonabant, which works as an appetite suppressant. It acts as a cannabinoid type I (CB1) receptor inhibitor and works to block these brain receptors, which influence factors such as food intake and body’s ability to break down sugars and fats in the blood. Over the course of treatment, a person loses considerable body weight as his/her food consumption reduces.

Related Results Lancet, BMJ studies sound concern over anti-obesity drug rimonabantRimonabant improves cardiovascular risk profileRimonabant improves cardiovascular risk profileNew drug application for rimonabant pulledRimonabant enhanced weight loss success, improved lipids The new 2-year study results are virtually superimposable on the 2-year outcomes of the phase III RIO--North America trial presented last fall at the annual scientific sessions of the American Heart Association (INTERNAL MEDICINE NEWS, Jan. 15, 2005, p. 52). Armed with data from over 6,600 overweight and obese participants in the two trials, plus two Sanofi-Aventis--sponsored 1-year phase III trials, the company plans to file before midyear for Food and Drug Administration and European Commission approval of rimonabant 20 mg/day for weight loss, a spokesman told this newspaper.